Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Phase ib trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Albertini, M. R.
  • Hank, J. A.
  • Schiller, J. H.
  • Khorsand, M.
  • Borchert, A. A.
  • Gan, J.
  • Bechhofer, R.
  • Storer, B.
  • Reisfeld, Ralph
  • Sondel, P. M.

publication date

  • August 1997

journal

  • Clinical Cancer Research  Journal

abstract

  • We conducted a Phase IB trial of antidisialoganglioside chimeric 14. 18 (ch14.18) antibody and interleukin 2 (IL-2) to determine the maximal tolerated dose (MTD), immunological effects, antitumor effects, and toxicity of this treatment combination. Twenty-four melanoma patients received immunotherapy with ch14.18 antibody and a continuous infusion of Roche IL-2 (1.5 x 10(6) units/m2/day) given 4 days/week for 3 weeks. The ch14.18 antibody (dose level, 2-10 mg/m2/day) was scheduled to be given for 5 days, before, during, or following initial systemic IL-2 treatment. The ch14.18 MTD was 7.5 mg/m2/day, and 15 patients were treated with the ch14.18 MTD. Immunological effects included the induction of lymphokine-activated killer activity and antibody-dependent cellular cytotoxicity by peripheral blood mononuclear cells. In addition, serum samples obtained following ch14.18 infusions were able to facilitate in vitro antibody-dependent cellular cytotoxicity. Antitumor activity included one complete response, one partial response, eight patients with stable disease, and one patient with >50% decrease of hepatic metastases in the face of recurrence of a s.c. lesion. Dose-limiting toxicities were a severe allergic reaction and weakness, pericardial effusion, and decreased performance status. Most patients treated at the MTD had abdominal, chest, or extremity pain requiring i.v. morphine. One patient had an objective peripheral neuropathy. This IL-2 and ch14.18 treatment combination induces immune activation in all patients and antitumor activity in some melanoma patients. We are attempting to enhance this treatment approach by addition of the anti-GD3 R24 antibody to this IL-2 and ch14.18 regimen.

subject areas

  • Adult
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibody-Dependent Cell Cytotoxicity
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Immunophenotyping
  • Immunotherapy
  • Interleukin-2
  • Killer Cells, Lymphokine-Activated
  • Lymphocyte Count
  • Lymphocytes
  • Male
  • Melanoma
  • Middle Aged
  • Neoplasm Metastasis
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • Tumor Cells, Cultured
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1078-0432

PubMed ID

  • 9815810
scroll to property group menus

Additional Document Info

start page

  • 1277

end page

  • 1288

volume

  • 3

issue

  • 8

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support